Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.48 |
| ▸ | LTB4R | Q15722 | 13/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 13/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8610596 | 0.84 | NR1H4 (0.67) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| Ly-255283 SCHEMBL4562255 | 0.80 | NR1H4 (0.69) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL7646400 | 0.77 | LTB4R (0.71) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL9417960 | 0.75 | NR1H4 (0.63) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL9417870 | 0.75 | NR1H4 (0.46) | NR1H4LTB4RLTB4R2MEN1ALDH1A1 | |
| SCHEMBL7646883 | 0.75 | LTB4R (0.73) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL7610606 | 0.70 | MAPT (0.31) | NR1H4LTB4RLTB4R2ALDH1A1THRB | |
| SCHEMBL8565284 | 0.68 | NR1H4 (0.56) | NR1H4LTB4RLTB4R2 | |
| SCHEMBL20915217 | 0.68 | CNR2 (0.34) | NR1H4 | |
| SCHEMBL20915250 | 0.68 | CNR2 (0.34) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | claimed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| US-20190216790-A1 | Methods for Treating Pruritis | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-07-18 | — | — | US | disclosed |
| US-6342510-B1 | ANTIINFLAMMATORY AGENTS AND ENZYME INHIBITORS | G. D. SEARLE & CO. | 2002-01-29 | — | — | US | disclosed |
| WO-2001034133-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034134-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| WO-2001034199-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190216790-A1 | Methods for Treating Pruritis | ITCH, CYSLTR2, CYSLTR1 | NR1H4 79/4885LTB4R 8/4885LTB4R2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.